Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A42793 | 33453331 | J Hepatol | Yet more evidence that MAFLD is more than a name change. | 2021 | Details |
| A42794 | 33453330 | J Hepatol | MAFLD: A holistic view to redefining fatty liver disease. | 2021 | Details |
| A42795 | 33453327 | J Hepatol | MAFLD: A game changer redefining fatty liver disease for adults and children. | 2021 | Details |
| A42796 | 33452704 | J Magn Reson Imaging | Reply to "Multiparametric MRI in patients with nonalcoholic fatty liver disease". | 2021 | Details |
| A42797 | 33449367 | Hepatology | Ceramide Salvage, Gut Mucosal Immunoglobulin A Signaling, and Diet-Induced NASH. | 2021 | Details |
| A42798 | 33446474 | Clin Res Hepatol Gastroenterol | Irinotecan-induced NASH and liver failure. | 2021 | Details |
| A42799 | 33445170 | J Clin Invest | Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer. | 2021 | Details |
| A42800 | 33442020 | Nat Rev Gastroenterol Hepatol | Full-spectrum transcriptomics in NAFLD. | 2021 | Details |
| A42801 | 33442011 | Nat Med | Therapy for NASH. | 2021 | Details |
| A42802 | 33441256 | Clin Res Hepatol Gastroenterol | Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease? | 2021 | Details |
| A42803 | 33438298 | J Magn Reson Imaging | Response to letter: Multiparametric magnetic resonance imaging in patients with nonalcoholic fatty liver disease. | 2021 | Details |
| A42804 | 33437891 | Transl Gastroenterol Hepatol | Similarities and differences between non-alcoholic fatty liver disease (NAFLD) & alcohol-associated liver disease (ALD). | 2021 | Details |
| A42805 | 33426918 | Clin Trials | Importance of incorporating quantitative imaging biomarker technical performance characteristics when estimating treatment effects. | 2021 | Details |
| A42806 | 33425000 | Evid Based Complement Alternat Med | Ulmus parvifolia Jacq. Exhibits Antiobesity Properties and Potentially Induces Browning of White Adipose Tissue. | 2020 | Details |
| A42807 | 33421313 | Mol Nutr Food Res | Metabolism and Inflammation: New Synergies and Insights. | 2021 | Details |
| A42808 | 33420415 | Nat Rev Gastroenterol Hepatol | Nonalcoholic fatty liver disease: another leap forward. | 2021 | Details |
| A42809 | 33394628 | J Clin Gastroenterol | COVID-19 in Chronic Liver Disease and Liver Transplantation: A Clinical Review. | 2021 | Details |
| A42810 | 33386162 | J Hepatol | Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications". | 2020 | Details |
| A42811 | 33385573 | Ann Hepatol | Non-invasive diagnosis of non-alcoholic fatty liver disease using an algorithm combining clinical indexes and ultrasonographic measures. | 2020 | Details |
| A42812 | 33385572 | Ann Hepatol | Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. | 2020 | Details |
| A42813 | 33378945 | Biomed Pharmacother | A novel quantitative assay for analysis of GLUT4 translocation using high content screening. | 2020 | Details |
| A42814 | 33377648 | Clin Transl Med | Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling. | 2017 | Details |
| A42815 | 33359898 | J Hepatol | Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". | 2020 | Details |
| A42816 | 33358254 | J Hepatol | Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications. | 2020 | Details |
| A42817 | 33355004 | Crit Rev Food Sci Nutr | Interaction between iron and omega-3 fatty acids metabolisms: where is the cross-link? | 2020 | Details |
| A42818 | 33354565 | Biomed Res Int | Sex Difference of Ribosome in Stroke-Induced Peripheral Immunosuppression by Integrated Bioinformatics Analysis. | 2020 | Details |
| A42819 | 33353459 | Thyroid | Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta. | 2021 | Details |
| A42820 | 33347955 | Mol Cell Endocrinol | RORα regulates hepatic lipolysis by inducing transcriptional expression of PNPLA3 in mice. | 2020 | Details |
| A42821 | 33347953 | J Hepatol | Clinical utility of the MAFLD definition. | 2020 | Details |
| A42822 | 33347353 | AJR Am J Roentgenol | Reply to "Biomarkers for High-Risk Nonalcoholic Fatty Liver Disease: Beyond Portal Venous Pulsatility Index". | 2021 | Details |
| A42823 | 33347352 | AJR Am J Roentgenol | Biomarkers for High-Risk Nonalcoholic Fatty Liver Disease: Beyond Portal Venous Pulsatility Index. | 2021 | Details |
| A42824 | 33346689 | Physiol Genomics | Cell-free DNA and RNA-measurement and applications in clinical diagnostics with focus on metabolic disorders. | 2020 | Details |
| A42825 | 33345412 | Liver Transpl | Nonalcoholic Fatty Liver Disease: A Special Consideration in Transjugular Intrahepatic Portosystemic Shunts? | 2021 | Details |
| A42826 | 33340579 | J Hepatol | Is the name 'NAFLD' too big to fail? Let's keep it for 'nutrition-associated fatty liver disease'. | 2020 | Details |
| A42827 | 33340578 | J Hepatol | Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling. | 2020 | Details |
| A42828 | 33340576 | J Hepatol | The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD. | 2020 | Details |
| A42829 | 33340575 | J Hepatol | Non-alcoholic fatty liver disease: Not time for an obituary just yet! | 2020 | Details |
| A42830 | 33340573 | J Hepatol | Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis. | 2020 | Details |
| A42831 | 33340572 | J Hepatol | A new definition for non-alcoholic fatty liver disease. | 2020 | Details |
| A42832 | 33340570 | J Hepatol | Two sides of NNMT in alcoholic and non-alcoholic fatty liver development. | 2020 | Details |
| A42833 | 33340111 | Hepatology | Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration. | 2021 | Details |
| A42834 | 33339610 | J Hepatol | Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?" | 2020 | Details |
| A42835 | 33338513 | J Hepatol | Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD. | 2020 | Details |
| A42836 | 33337742 | Clin Obstet Gynecol | Polycystic Ovarian Syndrome: Impact on Adult and Fetal Health. | 2021 | Details |
| A42837 | 33337585 | Ultrasound Q | Liver Stiffness Is Increased in Polycystic Ovary Syndrome and Related With Complement C1q/Tumor Necrosis Factor-Related Protein 3 Levels: A Point Shear Wave Elastography Study. | 2020 | Details |
| A42838 | 33328555 | Cell Mol Immunol | Monocyte-derived KCs (MoKCs) contribute to the KC pool in NASH. | 2020 | Details |
| A42839 | 33327917 | Curr Vasc Pharmacol | Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments. | 2021 | Details |
| A42840 | 33321005 | Acta Gastroenterol Belg | Metabolic dysfunction-associated fatty liver disease: a new clearer nomenclature with positive diagnostic criteria. | 2021 | Details |
| A42841 | 33319387 | Stat Med | Determination of correlations in multivariate longitudinal data with modified Cholesky and hypersphere decomposition using Bayesian variable selection approach. | 2020 | Details |
| A42842 | 33317844 | J Hepatol | Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD? | 2020 | Details |
| A42843 | 33317240 | Clin Mol Hepatol | Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try. | 2020 | Details |
| A42844 | 33310085 | Gastroenterology | Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. | 2020 | Details |
| A42845 | 33309167 | J Genet Genomics | Comprehensive lipidomics in apoM-/- mice reveals an overall state of metabolic distress and attenuated hepatic lipid secretion into the circulation. | 2020 | Details |
| A42846 | 33308438 | Lancet Gastroenterol Hepatol | Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis. | 2021 | Details |
| A42847 | 33308437 | Lancet Gastroenterol Hepatol | Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis. | 2021 | Details |
| A42848 | 33299030 | Sci Rep | Author Correction: Perceived stress and non-alcoholic fatty liver disease in apparently healthy men and women. | 2020 | Details |
| A42849 | 33297754 | Arterioscler Thromb Vasc Biol | The Dynamic Platelet Transcriptome in Obesity and Weight Loss. | 2020 | Details |
| A42850 | 33295318 | MEDICC Rev | Characterization of Deaths from Cirrhosis of the Liver in Cuba, 1987-2017. | 2020 | Details |
| A42851 | 33294679 | Heliyon | Association between serum IgG antibody titers against Porphyromonas gingivalis and liver enzyme levels: A cross-sectional study in Sado Island. | 2020 | Details |
| A42852 | 33283299 | Hepatology | Microbiome Biomarkers: One Step Closer in NAFLD Cirrhosis. | 2021 | Details |
| A42853 | 33282605 | Cureus | Effects of Oxidant-Antioxidant and Vitamin D Levels on Clinical and Laboratory Data in Children With Fatty Liver Disease. | 2020 | Details |
| A42854 | 33280222 | Liver Int | Re: Fouad Y, et al. The NAFLD-MAFLD debate: Eminence versus evidence. Liver Int. 2020 Nov 21. doi: 10.1111/liv.14739. | 2021 | Details |
| A42855 | 33280201 | Liver Int | Microalbuminuria in NAFLD patients: The impact of cardiovascular system. | 2020 | Details |
| A42856 | 33280172 | Clin Transplant | Sex differences in age at wait-list registration for liver transplantation with nonalcoholic steatohepatitis as primary indication. | 2020 | Details |
| A42857 | 33280151 | Hepatology | NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions. | 2021 | Details |
| A42858 | 33277657 | J Clin Endocrinol Metab | Elevated Circulating Glutamate Is Associated With Subclinical Atherosclerosis Independently of Established Risk Markers: A Cross-Sectional Study. | 2021 | Details |
| A42859 | 33275770 | Hepatology | Letter to the Editor: ABIDE in NAFLD: A Potential Game Changer in a Select Cohort of Cirrhosis. | 2021 | Details |
| A42860 | 33274619 | Pol Arch Intern Med | An elevated Fibrosis-4 score is associated with poor clinical outcomes in patients with sepsis: an observational cohort study. | 2020 | Details |
| A42861 | 33274438 | Hepatology | Letter to the Editor: ABIDE Model for Predicting Decompensation in Nonalcoholic Fatty Liver Disease-Related Cirrhosis. | 2021 | Details |
| A42862 | 33267571 | Minerva Gastroenterol (Torino) | Liver fibrosis in NAFLD patients: examining the opportunity to find a non-invasive, accurate and low-cost tool. | 2020 | Details |
| A42863 | 33259630 | Toxicol Sci | Gestational Cd Exposure in the CD-1 Mouse Induces Sex-Specific Hepatic Insulin Insensitivity, Obesity, and Metabolic Syndrome in Adult Female Offspring. | 2020 | Details |
| A42864 | 33257834 | Nat Rev Gastroenterol Hepatol | Semaglutide is safe and efficacious for NASH resolution. | 2021 | Details |
| A42865 | 33257823 | Nat Rev Endocrinol | Metabolic liver disease - what's in a name? | 2021 | Details |
| A42866 | 33253448 | Liver Int | Non-invasive diagnosis methods are needed in paediatric non-alcoholic fatty liver disease. | 2020 | Details |
| A42867 | 33250860 | Front Endocrinol (Lausanne) | Editorial: Metabolically Healthy and Unhealthy Obese Children and Adolescents. | 2020 | Details |
| A42868 | 33249727 | Liver Int | Low skeletal muscle mass and significant fibrosis in non-alcoholic fatty liver disease: Cause or effect? | 2020 | Details |
| A42869 | 33249025 | Clin Gastroenterol Hepatol | Controlled Attenuation Parameter in Nonalcoholic Fatty Liver Disease: The Thresholds Do Matter. | 2020 | Details |
| A42870 | 33248101 | Clin Gastroenterol Hepatol | External Validation of the Nonalcoholic Steatohepatitis Scoring System in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease in China. | 2020 | Details |
| A42871 | 33248097 | Clin Gastroenterol Hepatol | Reply. | 2020 | Details |
| A42872 | 33248075 | Clin Gastroenterol Hepatol | The Rising Tide of Nonalcoholic Fatty Liver Disease: How Much Time Until the Flood Reaches Our Coast? | 2020 | Details |
| A42873 | 33248071 | Clin Gastroenterol Hepatol | Alcohol Use in Patients With NAFLD. | 2020 | Details |
| A42874 | 33247737 | Toxicol Sci | Inhibition of Acetyl-CoA Carboxylase Causes Malformations in Rats and Rabbits: Comparison of Mammalian Findings and Alternative Assays. | 2021 | Details |
| A42875 | 33247713 | Endocr Rev | Metabolic Consequences of Solid Organ Transplantation. | 2021 | Details |
| A42876 | 33235387 | Cell Mol Immunol | Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. | 2020 | Details |
| A42877 | 33231259 | J Clin Endocrinol Metab | A Noncoding Variant Near PPP1R3B Promotes Liver Glycogen Storage and MetS, but Protects Against Myocardial Infarction. | 2021 | Details |
| A42878 | 33228942 | Pediatr Clin North Am | Pulmonary Manifestations of Gastrointestinal, Pancreatic, and Liver Diseases in Children. | 2021 | Details |
| A42879 | 33228454 | Annu Rev Physiol | The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe? | 2020 | Details |
| A42880 | 33223215 | J Hepatol | NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues. | 2020 | Details |
| A42881 | 33220266 | Cell Mol Gastroenterol Hepatol | Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis. | 2020 | Details |
| A42882 | 33220249 | Metabolism | Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19. | 2020 | Details |
| A42883 | 33217094 | Liver Int | Reply to: Pulmonary function is associated with fibrosis severity in patients with biopsy-proven nonalcoholic fatty liver disease. | 2020 | Details |
| A42884 | 33205875 | Aliment Pharmacol Ther | Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening. Authors' reply. | 2020 | Details |
| A42885 | 33205873 | Aliment Pharmacol Ther | Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening. | 2020 | Details |
| A42886 | 33202751 | Pathogens | Porphyromonas gingivalis and Its Systemic Impact: Current Status. | 2020 | Details |
| A42887 | 33202092 | Liver Int | Genetic insight into COVID-19 related liver injury: A note on MBOAT7. | 2020 | Details |
| A42888 | 33190748 | Clin Gastroenterol Hepatol | Use of FibroScan-AST Score to Stratify High-Risk Nonalcoholic Steatohepatitis in US Veterans. | 2020 | Details |
| A42889 | 33189580 | Can J Diabetes | Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. | 2020 | Details |
| A42890 | 33188417 | J Nutr | Minor Changes in the Composition and Function of the Gut Microbiota During a 12-Week Whole Grain Wheat or Refined Wheat Intervention Correlate with Liver Fat in Overweight and Obese Adults. | 2021 | Details |
| A42891 | 33187919 | Dig Liver Dis | Reply to "Does MAFLD really increase the severity of COVID-19?" | 2020 | Details |
| A42892 | 33180029 | J Pharmacol Exp Ther | Correction to "The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight". | 2020 | Details |